Business Description
Novakand Pharma AB
NAICS : 325412
SIC : 2834
ISIN : SE0015658570
Total Employee Number:
5Compare
Compare
Traded in other countries / regions
3EE0.GermanyNOVKAN.Sweden IPO Date
2011-03-10Description
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.9 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.6 | |||||
3-Year EPS without NRI Growth Rate | 35 | |||||
3-Year FCF Growth Rate | 32.1 | |||||
3-Year Book Growth Rate | -54.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.44 | |||||
9-Day RSI | 47.06 | |||||
14-Day RSI | 48.14 | |||||
3-1 Month Momentum % | -99.64 | |||||
12-1 Month Momentum % | -99.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.03 | |||||
Quick Ratio | 10.03 | |||||
Cash Ratio | 9.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -124.37 | |||||
ROA % | -112.38 | |||||
ROIC % | -206.73 | |||||
3-Year ROIIC % | -74.28 | |||||
ROCE % | -77.93 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.27 | |||||
PB Ratio | 0.36 | |||||
EV-to-EBIT | 1.36 | |||||
EV-to-EBITDA | 1.36 | |||||
EV-to-FCF | 1.33 | |||||
Earnings Yield (Greenblatt) % | 73.53 | |||||
FCF Yield % | -560.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novakand Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.036 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.36 | ||
| 3-Year Sortino Ratio | -0.53 | ||
| Volatility % | 194.37 | ||
| 14-Day RSI | 48.14 | ||
| 14-Day ATR (€) | 0.000999 | ||
| 20-Day SMA (€) | 0.0001 | ||
| 12-1 Month Momentum % | -99.88 | ||
| 52-Week Range (€) | 0.0001 - 0.1552 | ||
| Shares Outstanding (Mil) | 121.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novakand Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novakand Pharma AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 135 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 44 days | ||
| General meeting for 2026 | 2026-05-26 16:00 | 0.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-22 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-04-24 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-21 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-22 | 0.06 (+0.00%) | ||
| General meeting for 2025 | 2025-05-26 16:00 | 0.08 (+17.49%) | ||
| First quarter earnings results for 2025 | 2025-05-23 | 0.08 (+12.21%) |
Show
Entries
Novakand Pharma AB Frequently Asked Questions
What is Novakand Pharma AB(FRA:3EE0)'s stock price today?
The current price of FRA:3EE0 is €0.00. The 52 week high of FRA:3EE0 is €0.16 and 52 week low is €0.00.
When is next earnings date of Novakand Pharma AB(FRA:3EE0)?
The next earnings date of Novakand Pharma AB(FRA:3EE0) is 2026-08-21 Est..
Does Novakand Pharma AB(FRA:3EE0) pay dividends? If so, how much?
Novakand Pharma AB(FRA:3EE0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Novakand Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers